IDCRC Congratulates Incoming NIAID Director Dr. Jeanne Marrazzo
The Infectious Diseases Clinical Research Consortium (IDCRC) Leadership Group and Vaccine & Treatment Evaluation Unit (VTEU) leadership congratulates Dr. Jeanne Marrazzo on her selection as director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) part of the National Institutes of Health (NIH). Dr. Marrazzo is currently the Division of Infectious Diseases director at the University of Alabama at Birmingham. In addition to her many other roles, she also serves as the IDCRC Leadership Operations Center co-director and IDCRC Leadership Group Performance Evaluation co-chair.
"Dr. Marrazzo has been a core part of our leadership team since the inception of the IDCRC. Her vision, dedication and creativity were instrumental to our success in establishing and operationalizing this network in the midst of a global pandemic. While we will miss her contributions greatly, Dr. Marrazzo is an ideal choice to lead NIAID and we look forward to working with her in this new role," says Kathy Neuzil, MD, IDCRC PI and Leadership Group co-chair.
NIAID has funded the IDCRC since the consortium’s formation in 2019 and the VTEUs since 1962. The IDCRC and VTEUs work in tandem with the NIAID as a coordinated national and global network of scientific experts working to develop and test vaccines and other therapies to combat infectious diseases.
“The IDCRC leadership congratulates Dr. Marrazzo on her selection as director of the U.S. National Institute of Allergy and Infectious Diseases. We thank her for her terrific contributions to launching the IDCRC network and to the work of the IDCRC during the COVID-19 pandemic. Her commitment to excellence, quality, and to prevention and treatment of infections in underserved populations is exceptional," says David Stephens, MD, IDCRC contact PI and Leadership Group co-chair.
About the IDCRC
The IDCRC, consisting of the Vaccine Treatment and Evaluation Units (VTEUs) and the IDCRC Leadership Group (under award number UM1AI148684), was formed in 2019 to support the planning and implementation of infectious diseases clinical research that efficiently addresses the scientific priorities of NIAID. The consortium includes infectious diseases leaders and clinical researchers from Emory University, University of Maryland School of Medicine, Baylor College of Medicine, Cincinnati Children’s Medical Center and University of Cincinnati, FHI360, Fred Hutchinson Cancer Research Center, Johns Hopkins University, Kaiser Permanente Washington Health Research Institute, New York University, Saint Louis University, Vanderbilt University Medical Center, University of Alabama at Birmingham, University of Rochester, University of Washington, other affiliated sites and NIAID.